目的 通过分析乙酰辅酶A羧化酶(ACC)抑制剂相关药物及其全球专利布局情况，为国内制药企业的新药研发及专利保护提供借鉴。方法 运用定性和定量的分析，对ACC抑制剂药物的全球专利进行检索、标引、统计和分析，得出结论。结果 对于重点产品市场，同族专利构建是重点，而作为产品核心保护工具，化合物专利发挥着主要作用。结论 目前ACC抑制剂药物的全球专利尚处于早期布局阶段，国内制药企业可以根据研发策略择机进行晶型、组合物等外围专利布局。
Abstract
OBJECTIVE To analyze the ACC inhibitor drugs and their layout of global patents, thus to provide experience for the domestic pharmaceutical enterprises in the R&D and patent protection. METHODS Using qualitative and quantitative analysis, the global patents of ACC inhibitor drugs were searched, indexed, statisticed and analyzed to draw the conclusion. RESULTS Patent family is key for the important market and the chemical compound patent plays a major role. CONCLUSION The global patents of ACC inhibitor drugs are still on the early stage, and the domestic pharmaceutical enterprises could construct the crystal and composition patents in the surrounding patent layouts at the right time according the R&D strategies.
关键词
乙酰辅酶A羧化酶抑制剂 /
全球专利 /
专利族
{{custom_keyword}} /
Key words
ACC inhibitor drug /
global patent /
patent family
{{custom_keyword}} /
中图分类号：
R951
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] XIE L S, TAN X F. Summary of the gene research on acetyl-CoA carboxylase.J Central South Forestry Univ(中南林学院学报), 2005, 25(4): 89-95.
[2] LI Y, KONG W B, NIU S Q, et al. Difference and similarity analysis of acetyl-CoA carboxylase between different species . J Lanzhou Univ(Nat Sci)(兰州大学学报:自然科学版), 2013, 49(5): 682-687.
[3] YASUMA T, KAMATA M, YAMASHITA T, et al. Bicyclic compound: China, 201180066388.X . 2013-10-09.
[4] MATTHEW P B, MICHAEL D B. Recent advances in the development of acetyl-CoA carboxylase(ACC) inhibitors for the treatment of metabolic disease .J Med Chem, 2015, 58 (2): 525-536.
[5] BIOON: Gilead to acquire Nimbus Subsidiary and its ACC inhibitor program for up to $1.2B .Bioon, 2016. http://news.bioon.com/article/6681137.html
[6] QIAN L N, ZHANG C C, HUANG L. Histone deacetylase inhibitors and related patent information.Chin J New Drugs (中国新药杂志), 2016, 25(5): 485-517.
[7] Pfizer . . http://baike.so.com/doc/2901711-3062099.html
[8] Takeda . . http://www.takeda.co.jp/
[9] Takeda . . http://www.healthr.com/topic/110629/
Merck & Co Inc . . http://baike.so.com/doc/6807885-7024836.html
Merck subsidiaries: Japan's Banyu Pharmaceutical launched the medium-term plan . . http://info.pharmacy.hc360.com/2005/03/18104627650.shtml
Gilead sciences announces acquisition of Nimbus Therapeutics′ acetyl-CoA carboxylase (ACC) program for NASH and other liver diseases . . http://nimbustx.com/news-events/press-releases/gilead-sciences-announces-acquisition-nimbus-therapeutics-acetyl-coa
ZHANG H, LIU G Y. Patent family strategy analysis of lipitor.Chin Pharm J(中国药学杂志), 2014, 49(5): 437-440.
QIAN L N, ZHANG C C, HUANG L. Patent analysis of antiviral drugs from Gilead company . Chin J New Drugs (中国新药杂志), 2015, 24(18): 2041-2051.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
湖北省第一批知识产权示范建设企业建设工程(鄂知办〔2014〕55号)
{{custom_fund}}
PDF(1662 KB)
